<?xml version='1.0' encoding='utf-8'?>
<document id="25851691"><sentence text="Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects."><entity charOffset="10-19" id="DDI-PubMed.25851691.s1.e0" text="lopinavir" /><entity charOffset="20-29" id="DDI-PubMed.25851691.s1.e1" text="ritonavir" /><entity charOffset="75-87" id="DDI-PubMed.25851691.s1.e2" text="prostacyclin" /><pair ddi="false" e1="DDI-PubMed.25851691.s1.e0" e2="DDI-PubMed.25851691.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s1.e0" e2="DDI-PubMed.25851691.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25851691.s1.e0" e2="DDI-PubMed.25851691.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25851691.s1.e1" e2="DDI-PubMed.25851691.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25851691.s1.e1" e2="DDI-PubMed.25851691.s1.e2" /></sentence><sentence text="This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679"><entity charOffset="66-75" id="DDI-PubMed.25851691.s2.e0" text="lopinavir" /><entity charOffset="76-85" id="DDI-PubMed.25851691.s2.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25851691.s2.e0" e2="DDI-PubMed.25851691.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s2.e0" e2="DDI-PubMed.25851691.s2.e1" /></sentence><sentence text="" /><sentence text="This was an open label, randomized, single centre, two way, crossover study" /><sentence text=" Twenty healthy male subjects were treated with a single dose of 400 µg selexipag alone and in combination with multiple doses of lopinavir/ritonavir (400/100 mg) twice daily"><entity charOffset="130-139" id="DDI-PubMed.25851691.s5.e0" text="lopinavir" /><entity charOffset="140-149" id="DDI-PubMed.25851691.s5.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25851691.s5.e0" e2="DDI-PubMed.25851691.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s5.e0" e2="DDI-PubMed.25851691.s5.e1" /></sentence><sentence text="" /><sentence text="The results showed that lopinavir/ritonavir approximately doubled the exposure to selexipag"><entity charOffset="24-33" id="DDI-PubMed.25851691.s7.e0" text="lopinavir" /><entity charOffset="34-43" id="DDI-PubMed.25851691.s7.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25851691.s7.e0" e2="DDI-PubMed.25851691.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s7.e0" e2="DDI-PubMed.25851691.s7.e1" /></sentence><sentence text=" The area under the plasma concentration-time curve from time zero to infinity (AUC(0,∞) and the maximum plasma concentration (Cmax) of selexipag were 2" /><sentence text="2- and 2" /><sentence text="1-fold higher, respectively, than under selexipag alone, with a 90% confidence interval (CI) of the geometric mean ratio (GMR) of 1" /><sentence text="9, 2" /><sentence text="7 and 1" /><sentence text="7, 2" /><sentence text="6, respectively" /><sentence text=" For ACT-333679, the clinically more relevant component of selexipag, systemic exposure was increased by 8% (GMR of AUC(0,∞) 1" /><sentence text="1, 90% CI 0" /><sentence text="9, 1" /><sentence text="3), when lopinavir/ritonavir was co-administered with selexipag"><entity charOffset="9-18" id="DDI-PubMed.25851691.s18.e0" text="lopinavir" /><entity charOffset="19-28" id="DDI-PubMed.25851691.s18.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25851691.s18.e0" e2="DDI-PubMed.25851691.s18.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s18.e0" e2="DDI-PubMed.25851691.s18.e1" /></sentence><sentence text=" The most frequently reported adverse event (AE) was headache" /><sentence text=" A single dose of selexipag, administered either alone or together with multiple doses of lopinavir/ritonavir, was safe and well tolerated"><entity charOffset="90-99" id="DDI-PubMed.25851691.s20.e0" text="lopinavir" /><entity charOffset="100-109" id="DDI-PubMed.25851691.s20.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25851691.s20.e0" e2="DDI-PubMed.25851691.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s20.e0" e2="DDI-PubMed.25851691.s20.e1" /></sentence><sentence text="" /><sentence text="Lopinavir/ritonavir does not affect the PK parameters of selexipag and ACT-333679 to a clinically relevant extent"><entity charOffset="0-9" id="DDI-PubMed.25851691.s22.e0" text="Lopinavir" /><entity charOffset="10-19" id="DDI-PubMed.25851691.s22.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25851691.s22.e0" e2="DDI-PubMed.25851691.s22.e0" /><pair ddi="false" e1="DDI-PubMed.25851691.s22.e0" e2="DDI-PubMed.25851691.s22.e1" /></sentence><sentence text=" Therefore, adaptation of the selexipag dose is not required when co-administered with inhibitors of the organic anion-transporting polypeptide (OATP) 1B1/ 1B3, P-glycoprotein (P-gp) and/or CYP3A4" /><sentence text="" /></document>